Literature DB >> 15386112

Structure-activity relationships for three macrolide antibiotics in Haemophilus influenzae.

Susan Mabe1, Jessica Eller, W Scott Champney.   

Abstract

A prior study examining differences in the activities of erythromycin and azithromycin on cellular functions in the Gram-negative pathogen, Haemophilus influenzae, revealed a marked difference in their inhibitory activities. The study revealed that protein synthesis and 50S ribosomal subunit assembly were equal targets for inhibition by azithromycin while erythromycin was a preferential inhibitor of translation. This contrast in inhibitory activities stimulated a comparative analysis of three additional antibiotics: clarithromycin, flurithromycin and roxithromycin. Each compound was tested over a concentration range for inhibitory effects on cellular processes. Clarithromycin was the most effective inhibitor of protein synthesis with an IC(50) of 5.6 microg/mL, followed by flurithromycin at 6 microg/mL, and roxithromycin at 9 microg/mL. IC(50) values for antibiotic effects on viable cell counts and growth rates were similar to those obtained for protein synthesis. Flurithromycin had the strongest effect on 50S ribosomal subunit formation with an IC(50) of 8 microg/mL, followed by clarithromycin and roxithromycin, at 9.0 microg/mL and 12.5 microg/mL respectively. 30S ribosomal subunit formation in cells treated with flurithromycin and roxithromycin was also reduced to some extent. Pulse-and-chase labeling kinetics examining subunit assembly rates verified the slower synthesis rate of the subunits in the presence of each macrolide. The results are discussed in terms of structural differences of these macrolides and their differential inhibitory effects on both cellular targets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15386112     DOI: 10.1007/s00284-004-4312-9

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  4 in total

1.  Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Ana María Ríos; Mónica Fonseca-Aten; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana María Gómez; George H McCracken; Octavio Ramilo; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.

Authors:  Rafael Szczepanowski; Irene Krahn; Nadine Bohn; Alfred Pühler; Andreas Schlüter
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

3.  Erythromycin- and chloramphenicol-induced ribosomal assembly defects are secondary effects of protein synthesis inhibition.

Authors:  Triinu Siibak; Lauri Peil; Liqun Xiong; Alexander Mankin; Jaanus Remme; Tanel Tenson
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

4.  Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.

Authors:  Mitchell H Friedlaender; Eugene Protzko
Journal:  Clin Ophthalmol       Date:  2007-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.